Research Analysts Issue Forecasts for CMPX Q2 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Leerink Partnrs issued their Q2 2026 earnings per share (EPS) estimates for Compass Therapeutics in a research note issued to investors on Wednesday, November 26th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of ($0.10) for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Leerink Partnrs also issued estimates for Compass Therapeutics’ Q4 2026 earnings at ($0.11) EPS.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06.

Several other analysts have also issued reports on the stock. Compass Point set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, October 6th. Wall Street Zen raised shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Lifesci Capital initiated coverage on Compass Therapeutics in a research report on Monday, October 6th. They set an “outperform” rating and a $10.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. Finally, D. Boral Capital reissued a “buy” rating and set a $30.00 price objective on shares of Compass Therapeutics in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.90.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock opened at $5.39 on Thursday. The stock has a market capitalization of $958.67 million, a P/E ratio of -11.98 and a beta of 1.48. Compass Therapeutics has a 52-week low of $1.33 and a 52-week high of $5.40. The stock’s 50-day simple moving average is $4.13 and its 200 day simple moving average is $3.25.

Hedge Funds Weigh In On Compass Therapeutics

A number of large investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in Compass Therapeutics by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company’s stock worth $463,000 after buying an additional 5,590 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Compass Therapeutics by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company’s stock worth $566,000 after acquiring an additional 11,689 shares during the last quarter. Deutsche Bank AG purchased a new stake in shares of Compass Therapeutics in the 1st quarter valued at $194,000. Nuveen LLC purchased a new stake in shares of Compass Therapeutics in the 1st quarter valued at $579,000. Finally, American Century Companies Inc. bought a new position in shares of Compass Therapeutics during the 1st quarter valued at $140,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.